Since the Drug Supply Chain Security Act (DSCSA) was enacted nearly 10 years ago, healthcare supply chain stakeholders have made steady progress in meeting regularly (through HDA and other settings) to discuss compliance strategies, establish recommended guidelines and build consensus on key milestones.
With the Delta variant surging across the United States, the fight against COVID-19 — and in turn, the most extensive vaccination campaign in our country’s history — is far from over. As the effects of the virus continue to reverberate, the Biden administration recently authorized booster shots, and the Food and Drug Administration granted full approval of the first COVID-19 vaccine in an effort to increase vaccination rates across the U.S.
Earlier this month, HDA published two new resources for supply chain stakeholders to ensure the proper handling of new products moving through the supply chain and removal of products that are recalled or need to be withdrawn.
HDA recently sponsored and participated in the Milken Institute’s 2021 Future of Health Summit. This year’s event, held on June 22–23, brought together industry experts, public health leaders and elected officials for insightful policy discussions on a variety of issues that are shaping healthcare in our country.
HDA President and CEO Chip Davis recently spoke at the 2021 BLC Online about the unique role of the healthcare distribution industry in combating COVID-19, how distributors continue to rise to its challenges and what is still needed to turn the corner on the pandemic, among other association priorities.